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a1 ANTI-TRYPSIN (AAT-1), AUGMENTS DCS AND FREQUENCY OF REGU-
LATORY T CELLS (T reg), MODULATES GVHD, AND INCREASES SURVIVAL
AFTER ALLOGENEIC TRANSPLANTATION
Marcondes, A.M.Q.1, Lesnikova, M.1, Georges, G.1,3, Mielcarek, M.1,3,
Dinarello, C.A.2, Deeg, H.J.1,3 1Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA; 2University of Colorado, Denver, CO; 3University of
Washington, Seattle, WA
Graft-versus-host disease (GVHD) is an important complication
of allogeneic hematopoietic cell transplantation (HCT).We showed
in a minor antigen mismatched murine transplant model that treat-
ment with human (serum derived) alpha-1-anti-trypsin (AAT) pre-
vented or attenuated acute GVHD and resulted in significantly
improved survival (p\0.04). AAT reduced production of pro-inflam-
matory cytokines and induced anti-inflammatory cytokines. In this
model pro-inflammatory cytokines such as IL-1B and IL-32 were re-
duced while anti-inflammatory cytokines such as IL-1RA were in-
creased. This shift in cytokine levels suggested a possible impact
on the function of antigen presenting cells, includingDendritic Cells
(DCs) and T cell activation. DCs are specialized to capture and pro-
cess antigens for presentation on MHC products and modify subse-
quent differentiation of T cells. We hypothesized that alteration of
cytokine levels would modify the spectrum of T cells. In a dog model
of unrelated DLA non-identical HCT we showed that AAT given
every other day for 3 doses (60 mg/kg/day), resulted in improvement
of clinical manifestations of active acute GVHD and concurrently
reduced the expression of TNFa and IL-1b mRNA, while IL-1Ra
was increased. Strikingly, the proportion of CD4+CD25hi FoxP3+
Treg cells significantly increased in parallel with a decline in pro-in-
flammatory cytokines. Therefore, we extended our studies in AAT
treated mice and used multi-parameter flow cytometry to detect
changes in spleen and bone marrow cells, focusing on CD4+CD25hi
FoxP3+Treg cells andCD8+/CD205+DCs and expression ofMHC
class II in comparison to albumin treated controls. CD8+/CD205+
MHC class II DCs in the spleen increased 20 fold and CD4+CD25hi
FoxP3+ Treg cells 10 fold in AAT treated mice. Extensive literature
supports that CD8+/CD205+ DCs in the intestine and the spleen is
specialized to induce cell tolerance.
Conclusion:We propose that AAT delivered prophylactically in this
transplant model resulted in induction of CD4+CD25hi FoxP3+ Treg
cells, presumably facilitated via DCs maturation and expansion,
thereby contributing to the development of tolerance. In light of its
long safety record in humans, these findings suggest that AAT should
be tested as a novel strategy to mitigate clinical GVHD.
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THE IMPACT OF THE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS
I-RELATED CHAIN A (MICA) AND HUMAN LEUKOCYTE ANTIGEN (HLA)-
DP MISMATCHES ON SEVERE ACUTE GVHD IN PATIENTS RECEIVING
ALLOGENEIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTS
(AHPCT) FROM ADULT UNRELATED DONORS
Askar, M.1, Rybicki, L.2, Zhang, A.1, Thomas, D.1, Kalaycio, M.3,
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Background:The role of matching forMICA andHLA-DP (DP) in
AHPCT remains unclear. We investigate the impact of these mis-
matches (MM) on post-transplant outcomes.
Methods:We studied 269 patients (100 AML, 44 ALL, 42MDS, 31
NHL, 17 CML, and 35 others) who had AHPCT at our institute be-
tween 2000-2010. BM and PSC were the sources of HPC in 168 and
101 patients. Myeloablative and reduced intensity conditioning were
used in 202 and 67 patients. GVHD prophylaxis consisted of a calci-
neurin inhibitor andmycophenolate ormethotrexate.MICA andDP
genotyping was performed by rSSOP (One Lambda, Inc, CA). Cox
proportional hazards analysis was used to identify univariable and
multivariable prognostic factors for outcomes. Exploratory recursive
partitioning analysis (RPA) with log-rank splitting was used to eval-uate the combined effect of MICA and DP MM on outcomes. Out-
comes from groups identified by RPA were estimated using the
Kaplan-Meier method and compared using the log-rank test.
Results: The number of patients with 8/8 (A/B/C/DRB1), 7/8, and
6/8 matches were 219, 48, and 2 respectively. One and 2 MICAMM
were observed in 27 and 2 patients among 228 with samples available
for testing. One and 2DPMMwere observed in 139 and 80 patients.
Patients with 1-2MICAMMhad a significantly greater risk of severe
aGvHD (Grade III-IV) than those with no MICA MM (HR 3.05,
95% CI 1.52-6.12, P 5 0.002); 100-day incidence was 39% vs.
15%. Patients with 1-2 DPMM had a greater risk of severe aGvHD
than those with no DP MM (HR 3.15, 95% CI 0.97-10.20, P 5
0.06); 100-day incidence was 20% and 8%. These results remained
consistent in multivariable analysis (HRadj 2.78, 95% CI 1.38-5.59,
P 5 0.004 for MICA MM; HRadj 2.78, 95% CI 0.85-9.08, P 5
0.09 for DP MM). RPA identified 3 groups based on MICA and
DP MM, from highest to lowest risk: 1-2 MICA MM and 1-2 DP
MM, noMICA and 1-2DPMM, and noDPMM. 100-day incidence
of severe aGvHD among these three groups was 38%, 17%, and 8%
(P 5 0.002; log-rank test). Mismatches at MICA and DP were not
associated with time to neutrophil or platelet engraftment, cGvHD,
relapse, relapse mortality, non-relapse mortality, or survival.
Conclusion: MICA MM are associated with significantly increased
risk of severe aGVHD. Among patients with DP MM, MICA MM
further increases the risk of severe acute GvHD. Further investiga-
tion of these observations in larger cohorts is warranted.56
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NK cells play an important role in immunity against viruses and
malignancy. Alleles for KIR3DL1/S1 are associated with improved
outcome in HIV infection. Previous studies have shown differential
impact of associations between 3DL1 alleles (3DL1-high, -low,
-null) and Bw4 alleles (I80, T 80), where higher affinity combinations
appear to secure stronger NK response in viral control.
Because NK cells play an important role in HSCT we hypothe-
sized that 3DL1 alleles and their hierarchically binding Bw4 ligands
would have differential outcomes in HSCT. We performed donor
3DL1/S1 allele typing for 426 patients with myeloid malignancies
(AML 70.2%, CML 6.3%, MDS 23.5%) who received URD
HSCT. 349 patients received 10/10 HLA matched HSCT, 77 re-
ceived 9/10 or 8/10 HLA-matched. All patients received an ablative
conditioning regimen and 364 patients received T-replete allografts.
Overall Bw4-I80 donors were associated with higher relapse com-
pared to Bw6 homozygous and Bw4-T80 donors (HR 1.48; P 5
.05). Not surprisingly, this association was stronger in Bw4-I80 and
3DL1-positive donors (HR1.59; P5 .03).While therewere no overall
differences in outcomes among recipients of donors with 3DL1-null
(27.96%), 3DL1-high (41.70%) or 3DL1-low (25.83%) allotypes,
the combination of 3DL1-high and Bw4-I80 donors, compared with
3DL1-high and Bw6 homozygous or Bw4-T80 donors, were strongly
associatedwith relapse (HR 2.71; P5 .001).When the analysis was re-
stricted to AML patients alone (n 5 299), 3DL1-high and Bw4-I80
donors remained associated with higher relapse (HR 2.10; P 5 .04).
There was no association between 3DL1-high/Bw4 compound
genotypes and NRM or aGVHD, nor between 3DL1-null and
3DL1-low and Bw4 with any outcome. In contrast, we confirmed
in this cohort our previous findings that 3DS1-positive donors
S224 Oral Presentations(36%) were associated with less OM (HR 0.78; P 5 .04) and NRM
(HR 0.70; P 5 .02).
For the first time in HSCT, this study demonstrates the impact of
3DL1 allotypes inHSCT, where combinations of 3DL1-high and their
high affinity Bw4 alleles in the donor are associated with higher relapse
andOMin patients. Conversely, donor 3DS1 is associatedwith lessOM
and NRM. These data offer insights to differential controls of NK bi-
ology inHSCT and support not only KIR genotyping but KIR allotyp-
ing in order to select donors with the best KIR-HLA combinations to
maximize leukemic control while minimizing unwanted toxicities.57
HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING ANTI-
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Allogeneic hematopoietic cell transplant (HCT) is a widely used
therapy for hematologic malignancy. It is important to give the op-
tion of HCT to patients without an HLA-matched donor; this is
most acute for ethnic minorities. Haploidentical HCT may offer
the best or only chance for cure but often fails due to persistant ma-
lignancy or fatal toxicity. It is important to improve disease control
without increased toxicity of the regimen. We have shown that
CD45 radioimmunotherapy (RIT) delivers radiation to leukemic
sites, sparing normal organs. We hypothesize haploidentical HCT
may be enhanced via CD45RIT bymaximizing delivery to target tis-
sue with minimal toxicity by reducing total-body irradiation (TBI)
and chemotherapy.We performed studies to find the maximal inten-
sity of anti-leukemic RIT combined with haploidentical HCT while
preserving graft-versus-leukemia effects. We established an HCT
regimen in B6SJLF1/J mice (H-2Db haplotype) conditioned with
fludarabine (FLU, days -6 to -2), followed by TBI (250, 500, 750
cGy; day -1). Mice received 15 million donor (CB6F1/J, H-2Dd)
BM cells (day 0), then cyclophosphamide (CY) for graft-versus-
host disease (GvHD) prophylaxis (day +2). Chimerism was TBI
dose-dependent; mice receiving $500 cGy were fully chimeric 4
weeks post-HCT, persisting $8 months. We then treated
B6SJLF1/J mice with or without FLU and 200-400 mCi of 90Y-la-
beled anti-murine CD45 Ab (30F11, day -3), followed by 15 million
donor BM cells (day 0) and CY (day +2). All mice receiving 200 or
300 mCi 90Y-CD45Ab survived 30 days after HCTwith no evidence
of toxicity or GvHD. Four of 10 mice receiving 400 mCi 90Y-CD45
Ab died by day 25 due to toxicity. At day 25 blood was taken to detect
chimerism via flow cytometry. Three of 5 mice that received 200 mCi
90Y-CD45 Ab and FLU showed chimerism with 23-77% CD8+ T-
cells expressing H-2Dd. Four of 5 (80%) mice receiving 300 mCi
90Y-30F11 and 2/3 (67%) receiving 400 mCi 90Y-30F11, in the pres-
ence of FLU, were chimeric with 22-89% and 25-64%CD8+ donor
cells, respectively. Mice receiving 200, 300, or 400 mCi 90Y-CD45
Ab without FLU were chimeric with 10-71% donor cells in 4/5
(80%), 2/5 (40%) and 1/4 (25%) mice, respectively. These data sug-
gest anti-CD45 RIT may be a well-tolerated regimen allowing en-
graftment of haploidentical marrow without TBI and
chemotherapy. Current studies testing pretargeted RIT may im-
prove targeting of malignant CD45+ cells with reduced TBI and
FLU, and increased therapeutic index.IMMUNE RECONSTITUTION58
EARLY POST-TRANSPLANT WHOLE TUMOR CELL-BASED VACCINATION
ALTERS THE KINETICS OF T CELL RECONSTITUTION
Burkhardt, U.E.1, Desmarais, C.2, Robins, H.S.2, Wu, D.1, Wong, J.1,
Neuberg, D.1, Alyea, E.P.1, Soiffer, R.J.1,Wu, C.J.1 1Dana-Farber Can-
cer Institute, Boston, MA; 2Adaptive TCR Technologies, Seattle, WAWhole tumor cell-based vaccines administered in the early post-
transplant (HSCT) setting are a promising approach to enhance
graft-versus-leukemia responses. Our previous studies described
the detection of increasedCD8+T cells with specificity for autologous
chronic lymphocytic leukemia (CLL) cells in association with attain-
ment of molecular remission within 6 months post-HSCT that devel-
oped following early-post transplant tumor vaccination (initiating at
day 30-45). The series of vaccines were comprised of irradiated autol-
ogous tumor admixed with irradiated GM-CSF secreting bystander
cells. It is unknown how this early post-transplant intervention shapes
the reconstituting donor T cell repertoire. One approach to character-
ize this is through examining the kinetics of recovery of T cell receptor
(TCR) beta-chain diversity using recently developed methodologies
that apply deep sequencing techniques for the analysis of the highly
variable complementarity-determining region 3 (CDR3) of the
TCR. We therefore isolated na€ıve and memory T cells from the
CD8 andCD4 compartments from 12 patients (6with vaccine, 6 with-
out) at time points informative for thymic-independent (early; 4month
post-transplant) and thymic-dependent (late; 1 year post-transplant) T
cell immune recovery. The isolated cell subsets directly underwent
PCR amplification of the CDR3 region to generate a template library
that was then sequenced using the IlluminaGA2 system.We obtained
a median of 24,191 productive reads per sample (range 0-8,900,000).
To evaluate theTCRdiversity, we calculated the normalized probabil-
ity distribution (‘entropy’) of eachT cell compartment.Overall, we ob-
served that the 6 vaccinated subjects demonstrated a higher
normalized entropy at day 120 (p 5 0.008) and more unique CDR3
sequences (one-tailed t-test with unequal variance: p 5 0.03) com-
pared to non-vaccinated subjects. In particular, CD8+ memory and
na€ıve cells exhibited greater TCR diversity at days 120 and 365 in vac-
cinated than in non-vaccinated individuals. These results suggest that
early post-transplant vaccination exerts an active role in shaping T cell
reconstitution.Ongoing analyses focus on the integration ofTCR rep-
ertoire data with the assessment of minimal residue disease, immuno-
phenotyping and TCR excision circle (TREC) analysis. The results
gained within this study provide us with critical information as we for-
mulate the next generation of post-transplant cancer vaccines.59
POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT/Cy) PRESERVES EFFEC-
TOR (Teff) AND REGULATORY (Treg) T CELLS DURING EARLY IMMUNE
RECONSTITUTION AFTER ALLOGENEIC BONE MARROW TRANSPLANTA-
TION
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Emerging clinical data suggest that high-dose PT/Cy is effective
in preventing both acute and chronic GVHD, but the mechanisms
accounting for these effects have not been fully characterized. We
hypothesized that PT/Cy prevents acuteGVHD (aGVHD) by selec-
tively depleting highly proliferative alloreactive T cells stimulated
early after transplant, while sparing Tregs. We analyzed the pheno-
typic reconstitution of CD4+ T cells at days 30 and 60 after trans-
plant in a cohort of 47 consecutive patients (median age 50) that
received HLA-matched allografts and PT/Cy as sole GVHD pro-
phylaxis. CD4+Foxp3+ T cells were partitioned into three pheno-
typic fractions (Fr) with distinct functions: CD45RA+Foxp3+lo (Fr
I), CD45RA-Foxp3+hi (Fr II), and CD45RA-Foxp3+lo (Fr III), repre-
senting naive Tregs, activated Tregs, and non-suppressive, cytokine-
secreting Teff, respectively. In both patients with and without
aGHVD, Teff (Fr III) percentages were increased compared with
healthy donors (p 5 0.004), and were higher in patients with
aGVHD compared with patients without aGVHD (p5 0.0003). In-
terestingly, patients with aGVHD also had higher percentages of ac-
tivated Tregs (Fr II, p 5 0.01) compared with patients without
aGVHD. These relative increases in Fr II and III persisted despite
steroid-induced lymphopenia. The relative expansion of Tregs in pa-
tients with aGVHD was an unexpected finding, since aGVHD is as-
sociated with lower Tregs in studies using traditional GVHD
prophylaxis incorporating calcineurin inhibitors (CNIs). To assess
differential effects of PT/Cy and CNI on T cell reconstitution in
